Given the absence of an effective vaccine for protection against HIV-1 infection, passive
immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block …

Introduction Poor or inconsistent adherence to daily oral pre-exposure prophylaxis (PrEP)
has emerged as a key barrier to effective HIV prevention. The advent of potent long-acting …

Anti-HIV broadly neutralizing antibodies (bNAbs) offer a novel approach to treating,
preventing, or curing HIV. Pre-clinical models and clinical trials involving the passive transfer …

Viral diseases represent a major public health concerns and ever-present risks for
developing into future pandemics. Antiviral antibody therapeutics, either alone or in …

ABSTRACT Antibody CAP256-VRC26. 25 targets the second hypervariable region (V2) at
the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency, although …

Background Effective, long-acting prevention approaches are needed to reduce human
immunodeficiency virus (HIV) incidence. We evaluated the safety and pharmacokinetics of …

Monoclonal antibodies have been used successfully as recombinant protein therapy;
however, for HIV, multiple broadly neutralizing antibodies may be necessary. We used the …

Abstract CAP256V2LS, a broadly neutralizing monoclonal antibody (bNAb), is being
pursued as a promising drug for HIV-1 prevention. The total level of tyrosine-O-sulfation, a …

The human immunodeficiency virus (HIV) epidemic remains a formidable global health
concern, with 39 million people living with the virus and 1.3 million new infections reported …

Objective: This study was designed to provide information on the genetic diversity of HIV-1
and drug resistance mutations in Nigeria, as there is limited understanding of variants …